Olympus had agreed to sell its microscope unit to private equity firm Bain Capital for $3.1 billion as it speeds up the overhaul of its business portfolio to focus solely on medical technology
The microscope unit, which also manufactures industrial endoscopes and x-ray analyzers, will be transferred to Bain on January 4, subject to antitrust regulatory approvals in Japan and elsewhere.
Olympus stated that the transfer to Bain would benefit the company by allowing it to grow through more agile and flexible decision-making based on market needs.
Bain edged global private equity firms such as Carlyle Group and KKR & Co. for the right to acquire the microscope unit.
Olympus said the transfer to Bain would be in its best interest to allow the business to grow with more agile and flexible decision-making based on market needs.
Bain won over global private equity firms such as Carlyle Group and KKR & Co.
Bain owns flash memory chip maker Kioxia Holdings and is proceeding to a second bidding round for Toshiba.


NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons
Neuralink Expands Brain Implant Trials with 12 Global Patients
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



